These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 23249582)

  • 21. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
    Ryan GJ; Hardy Y
    J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of liraglutide on male fertility: a case report.
    Fontoura P; Cardoso MC; Erthal-Martins MC; Werneck C; Sartorio C; Ramos CF
    Reprod Biomed Online; 2014 Nov; 29(5):644-6. PubMed ID: 25246122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
    Hermansen K; Kolotkin RL; Hammer M; Zdravkovic M; Matthews D
    Prim Care Diabetes; 2010 Jul; 4(2):113-7. PubMed ID: 20444662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of type 2 diabetes with incretin-based therapies.
    Madsbad S
    Lancet; 2009 Feb; 373(9662):438-9. PubMed ID: 18819704
    [No Abstract]   [Full Text] [Related]  

  • 25. [Liraglutide reduces biomarkers and vascular risk in patients with diabetes mellitus type 2].
    García de Lucas MD; Olalla J; Sempere M
    Rev Med Chil; 2013 Dec; 141(12):1602-4. PubMed ID: 24728441
    [No Abstract]   [Full Text] [Related]  

  • 26. Combination therapy with liraglutide and sulfonylurea for a type 2 diabetic patient with high titer of anti-insulin antibodies produced by insulin therapy.
    Yoshida M; Asai M; Miyata M; Ogawa K; Maeda H; Oiso Y
    Diabetes Res Clin Pract; 2012 Jun; 96(3):e55-6. PubMed ID: 22257418
    [No Abstract]   [Full Text] [Related]  

  • 27. Liraglutide: from clinical trials to clinical practice.
    Gough SC
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():33-40. PubMed ID: 22405267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Beta-cell function in the foreground. GLP-1 based therapy of type 2 diabetes].
    Kern W
    MMW Fortschr Med; 2010 Jan; 151 Suppl 4():173-8. PubMed ID: 21595145
    [No Abstract]   [Full Text] [Related]  

  • 29. [Liraglutide in the treatment of diabetes type 2].
    Novak B; Metelko Z
    Lijec Vjesn; 2011; 133(7-8):269-76. PubMed ID: 22165195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exenatide and rare adverse events.
    Ahmad SR; Swann J
    N Engl J Med; 2008 May; 358(18):1970-1; discussion 1971-2. PubMed ID: 18456920
    [No Abstract]   [Full Text] [Related]  

  • 31. NICE approves liraglutide for diabetic patients not achieving glucose control.
    Mayor S
    BMJ; 2010 Sep; 341():c5062. PubMed ID: 20843934
    [No Abstract]   [Full Text] [Related]  

  • 32. Liraglutide in oral antidiabetic drug combination therapy.
    Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic use and adverse events of incretin-related drugs].
    Ishikawa M; Yamada Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
    [No Abstract]   [Full Text] [Related]  

  • 34. [Antidiabetics and the incretin system].
    Høibraaten E; Folkersen J
    Tidsskr Nor Laegeforen; 2008 Sep; 128(17):1985. PubMed ID: 18787580
    [No Abstract]   [Full Text] [Related]  

  • 35. Incretin therapy and its effect on body weight in patients with diabetes.
    Lind M
    Prim Care Diabetes; 2012 Oct; 6(3):187-91. PubMed ID: 22613745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analog.
    Giannoukakis N
    Curr Opin Investig Drugs; 2007 Oct; 8(10):842-8. PubMed ID: 17907061
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
    Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
    J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].
    Mannucci E
    G Ital Cardiol (Rome); 2011 Dec; 12(12 Suppl 2):3-4. PubMed ID: 22158420
    [No Abstract]   [Full Text] [Related]  

  • 39. GLP-1 provoked severe hypoglycemia in an individual with type 2 diabetes and a benign insulinoma.
    Ruby RJ; Armato JP; Pyke C; Peters AL
    Diabetes Care; 2014 Aug; 37(8):e177-8. PubMed ID: 25061148
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
    Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
    Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.